Executive Summary
Sirnaomics Ltd delivered a QQ2 2025 result set that underscores the company’s status as an early-stage RNA therapeutics player: minimal near-term revenue, substantial investment in R&D and G&A, and meaningful cash burn. Revenue for the quarter was USD 81,000, with a gross profit of USD 81,000 and a gross margin of 100% as cost of revenue was not reported, consistent with a development-stage biotech model without commercial products in revenue. However, operating expenses dominated the P&L, totaling USD 5.598 million (R&D USD 3.045 million and G&A USD 2.553 million), producing an EBITDA of USD -4.692 million and a net loss of USD -3.698 million, or -45.65% net margin. Diluted EPS stood at -0.0394. The quarter contributes to a broader burn profile typical of pre-commercial biotechs, raising questions about runway, funding strategy, and potential dilution risk.
Key Performance Indicators
Key Insights
Revenue: USD 81,000 (YoY -81.34%, QoQ +0.00%)
Gross Profit: USD 81,000; Gross Margin: 100.0% (YoY -43.94%, QoQ 0.00%)
Operating Income: USD -5,517,000; Operating Margin: -68.11% (YoY +16.81%, QoQ 0.00%)
Net Income: USD -3,698,000; Net Margin: -45.65% (YoY +28.32%, QoQ 0.00%)
EPS (Diluted): -0.0394 (YoY +39.76%, QoQ 0.00%)
R&D: USD 3.045 million; G&A: USD 2.553 million; D&A: USD 0.825 million
EBITDA: USD -4.692 million; EBITDARatio: -57.93%
Cash Flow Indicators: Operating Cash Flow pe...
Financial Highlights
Revenue: USD 81,000 (YoY -81.34%, QoQ +0.00%)
Gross Profit: USD 81,000; Gross Margin: 100.0% (YoY -43.94%, QoQ 0.00%)
Operating Income: USD -5,517,000; Operating Margin: -68.11% (YoY +16.81%, QoQ 0.00%)
Net Income: USD -3,698,000; Net Margin: -45.65% (YoY +28.32%, QoQ 0.00%)
EPS (Diluted): -0.0394 (YoY +39.76%, QoQ 0.00%)
R&D: USD 3.045 million; G&A: USD 2.553 million; D&A: USD 0.825 million
EBITDA: USD -4.692 million; EBITDARatio: -57.93%
Cash Flow Indicators: Operating Cash Flow per Share USD -0.0522; Free Cash Flow per Share USD -0.0528; Cash per Share USD 0.0733; Price-to-Sales Ratio 667.32; Debt/Leverage metrics show liquidity strains and unusual negative equity multipliers in this dataset.
Notes: All figures are USD and reflect QQ2 2025 (quarter ended 2025-06-30) unless stated otherwise; several balance-sheet ratios appear anomalous (e.g., negative debt-to-equity, extremely high price-to-sales) indicating data limitations and/or accounting quirks in the provided dataset.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
81.00K |
-81.34% |
0.00% |
| Gross Profit |
81.00K |
-43.94% |
0.00% |
| Operating Income |
-5.52M |
16.81% |
0.00% |
| Net Income |
-3.70M |
28.32% |
0.00% |
| EPS |
-0.04 |
39.76% |
0.00% |
Key Financial Ratios
operatingProfitMargin
-6811%
operatingCashFlowPerShare
$-0.05
freeCashFlowPerShare
$-0.05
Management Commentary
Transcript data not provided in the input. Management commentary from the QQ2 2025 earnings call could not be extracted or quoted from the supplied material. If you can provide the earnings call transcript, I will extract them by theme (strategy, operations, market conditions) and attach direct quotes with context.
Forward Guidance
No explicit forward guidance is included in the supplied data set. Given the pre-commercial stage of Sirnaomics and the current quarterly mix dominated by R&D and G&A spend with negligible revenue, the near-term trajectory will depend on pipeline progress, successful collaboration or licensing deals, and access to equity or debt financing. Investors should monitor: (1) any announced partnerships, milestone payments, or licensing arrangements related to STP705, STP707, STP355, STP369, STP779, STP902, and other candidates; (2) cash runway and any announced financing rounds; (3) updates on clinical readouts, regulatory milestones, or acceptance of INDs; (4) changes in headcount or SG&A intensity as the company pivots toward scalable programs. Assessment: Without near-term revenue catalysts, forecasted cash burn remains a critical risk; a credible path to profitability hinges on transitioning select pipeline assets into milestone-bearing collaborations or achieving value inflection via clinical outcomes and partner leverage.